SCHEDULE: Vestal Point Capital Discloses 9.2% Stake in Bicara
Beneficial Ownership Report
Vestal Point Capital, LP and Ryan Wilder have disclosed a beneficial ownership of 9.2% in Bicara Therapeutics Inc., totaling 5 million shares.
Summary
- Vestal Point Capital, LP and Ryan Wilder collectively reported beneficial ownership of 5,000,000 shares of Bicara Therapeutics Inc. Common Stock.
- This represents 9.2% of the company's outstanding Common Stock.
- The percentage is calculated based on 54,536,218 shares outstanding as of May 8, 2025, as reported in Bicara Therapeutics Inc.'s Form 10-Q for the quarter ended March 31, 2025.
- The shares are held by a certain fund and a managed account (the "Vestal Point Fund and Account") for which Vestal Point Capital, LP acts as investment adviser.
- Ryan Wilder is the Chief Investment Officer and Managing Partner of Vestal Point Capital, LP.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership without performance or strategic implications.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional stake may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | End of quarterly period for which Bicara Therapeutics Inc. filed its Form 10-Q. |
| 2025-05-08 | Date as of which 54,536,218 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-05-13 | Date Bicara Therapeutics Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-08-14 | Date the Schedule 13G statement was signed by the Reporting Persons. |
Keywords
Bicara Therapeutics, Vestal Point Capital, Ryan Wilder, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.